Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
What's Powering J&J's MedTech Growth Ahead of Q4 Release?
JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.
Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know
Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices
The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.
Johnson & Johnson reaches deal with US government to lower drug prices
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.
J&J's Innovative Medicine Segment in Q4: Here's What to Watch
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from the preceding trading day.
